Cargando…

Antineuronal Autoantibodies in the Cerebrospinal Fluid and Serum From 106 Patients With Recent-Onset Depression Compared With 106 Individually Matched Healthy Control Subjects

No large studies have investigated the prevalence of cerebrospinal fluid antineuronal autoantibodies in isolated depression. In this case-control study comparing 106 patients with isolated depression (ICD-10 code F32) with 106 healthy control subjects, cerebrospinal fluid and serum samples were test...

Descripción completa

Detalles Bibliográficos
Autores principales: Sørensen, Nina Vindegaard, Nilsson, Anna Christine, Orlovska-Waast, Sonja, Jeppesen, Rose, Christensen, Rune Haubo Bojesen, Benros, Michael Eriksen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593866/
https://www.ncbi.nlm.nih.gov/pubmed/37881586
http://dx.doi.org/10.1016/j.bpsgos.2022.10.007
_version_ 1785124524628377600
author Sørensen, Nina Vindegaard
Nilsson, Anna Christine
Orlovska-Waast, Sonja
Jeppesen, Rose
Christensen, Rune Haubo Bojesen
Benros, Michael Eriksen
author_facet Sørensen, Nina Vindegaard
Nilsson, Anna Christine
Orlovska-Waast, Sonja
Jeppesen, Rose
Christensen, Rune Haubo Bojesen
Benros, Michael Eriksen
author_sort Sørensen, Nina Vindegaard
collection PubMed
description No large studies have investigated the prevalence of cerebrospinal fluid antineuronal autoantibodies in isolated depression. In this case-control study comparing 106 patients with isolated depression (ICD-10 code F32) with 106 healthy control subjects, cerebrospinal fluid and serum samples were tested for 7 immunoglobulin G autoantibodies using commercial fixed cell-based assays. To explore validity of methods, positive samples were retested twice by cell-based assays and once by tissue-based assays (monkey cerebellum). The prevalence of any of the antineuronal autoantibodies in cerebrospinal fluid was 0.0% in both groups and the seroprevalence was 0.9% in both groups, based on consistent findings in cell-based assays. However, all samples were negative by the tissue-based assay. Evaluation of antineuronal autoantibodies in cerebrospinal fluid cannot be recommended routinely for patients with isolated depression of moderate severity. Future studies of isolated depression should consider much larger sample sizes and evaluation of antineuronal autoantibodies using modalities other than commercial kits.
format Online
Article
Text
id pubmed-10593866
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105938662023-10-25 Antineuronal Autoantibodies in the Cerebrospinal Fluid and Serum From 106 Patients With Recent-Onset Depression Compared With 106 Individually Matched Healthy Control Subjects Sørensen, Nina Vindegaard Nilsson, Anna Christine Orlovska-Waast, Sonja Jeppesen, Rose Christensen, Rune Haubo Bojesen Benros, Michael Eriksen Biol Psychiatry Glob Open Sci Techniques and Methods No large studies have investigated the prevalence of cerebrospinal fluid antineuronal autoantibodies in isolated depression. In this case-control study comparing 106 patients with isolated depression (ICD-10 code F32) with 106 healthy control subjects, cerebrospinal fluid and serum samples were tested for 7 immunoglobulin G autoantibodies using commercial fixed cell-based assays. To explore validity of methods, positive samples were retested twice by cell-based assays and once by tissue-based assays (monkey cerebellum). The prevalence of any of the antineuronal autoantibodies in cerebrospinal fluid was 0.0% in both groups and the seroprevalence was 0.9% in both groups, based on consistent findings in cell-based assays. However, all samples were negative by the tissue-based assay. Evaluation of antineuronal autoantibodies in cerebrospinal fluid cannot be recommended routinely for patients with isolated depression of moderate severity. Future studies of isolated depression should consider much larger sample sizes and evaluation of antineuronal autoantibodies using modalities other than commercial kits. Elsevier 2022-10-29 /pmc/articles/PMC10593866/ /pubmed/37881586 http://dx.doi.org/10.1016/j.bpsgos.2022.10.007 Text en © 2023 Published by Elsevier Inc on behalf of Society of Biological Psychiatry. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Techniques and Methods
Sørensen, Nina Vindegaard
Nilsson, Anna Christine
Orlovska-Waast, Sonja
Jeppesen, Rose
Christensen, Rune Haubo Bojesen
Benros, Michael Eriksen
Antineuronal Autoantibodies in the Cerebrospinal Fluid and Serum From 106 Patients With Recent-Onset Depression Compared With 106 Individually Matched Healthy Control Subjects
title Antineuronal Autoantibodies in the Cerebrospinal Fluid and Serum From 106 Patients With Recent-Onset Depression Compared With 106 Individually Matched Healthy Control Subjects
title_full Antineuronal Autoantibodies in the Cerebrospinal Fluid and Serum From 106 Patients With Recent-Onset Depression Compared With 106 Individually Matched Healthy Control Subjects
title_fullStr Antineuronal Autoantibodies in the Cerebrospinal Fluid and Serum From 106 Patients With Recent-Onset Depression Compared With 106 Individually Matched Healthy Control Subjects
title_full_unstemmed Antineuronal Autoantibodies in the Cerebrospinal Fluid and Serum From 106 Patients With Recent-Onset Depression Compared With 106 Individually Matched Healthy Control Subjects
title_short Antineuronal Autoantibodies in the Cerebrospinal Fluid and Serum From 106 Patients With Recent-Onset Depression Compared With 106 Individually Matched Healthy Control Subjects
title_sort antineuronal autoantibodies in the cerebrospinal fluid and serum from 106 patients with recent-onset depression compared with 106 individually matched healthy control subjects
topic Techniques and Methods
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593866/
https://www.ncbi.nlm.nih.gov/pubmed/37881586
http://dx.doi.org/10.1016/j.bpsgos.2022.10.007
work_keys_str_mv AT sørensenninavindegaard antineuronalautoantibodiesinthecerebrospinalfluidandserumfrom106patientswithrecentonsetdepressioncomparedwith106individuallymatchedhealthycontrolsubjects
AT nilssonannachristine antineuronalautoantibodiesinthecerebrospinalfluidandserumfrom106patientswithrecentonsetdepressioncomparedwith106individuallymatchedhealthycontrolsubjects
AT orlovskawaastsonja antineuronalautoantibodiesinthecerebrospinalfluidandserumfrom106patientswithrecentonsetdepressioncomparedwith106individuallymatchedhealthycontrolsubjects
AT jeppesenrose antineuronalautoantibodiesinthecerebrospinalfluidandserumfrom106patientswithrecentonsetdepressioncomparedwith106individuallymatchedhealthycontrolsubjects
AT christensenrunehaubobojesen antineuronalautoantibodiesinthecerebrospinalfluidandserumfrom106patientswithrecentonsetdepressioncomparedwith106individuallymatchedhealthycontrolsubjects
AT benrosmichaeleriksen antineuronalautoantibodiesinthecerebrospinalfluidandserumfrom106patientswithrecentonsetdepressioncomparedwith106individuallymatchedhealthycontrolsubjects